EXAS Share Price Performance
US$67.15
17.61 (35.55%)
13.6% undervalued intrinsic discount
US$77.68
Fair Value
Price US$67.15
AnalystHighTarget US$77.68
AnalystLowTarget US$47.73
AnalystConsensusTarget US$82.10
Fair ValueUS$77.68
Share Pricen/a
Exact Sciences Corporation Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 60 Fair Values set on narratives written by author
EXAS Community Narratives
AN
Fair Value US$77.68 13.6% undervalued intrinsic discount
AI And Genomics Will Expand Screening For Aging Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$47.73 40.7% overvalued intrinsic discount
Rising Reimbursement Pressures And Regulatory Hurdles Will Dampen Future Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$82.1 18.2% undervalued intrinsic discount
EXAS: Cancer Screening Expansion Will Balance Challenges From Blood Test Data
0users have liked this narrative
0users have commented on this narrative
34users have followed this narrative
EXAS: Cancer Screening Expansion Will Balance Challenges From Blood Test Data
Key Takeaways Broadening payer coverage and demographic trends toward an older population are positioning Exact Sciences for sustained and expanding revenue opportunities from core and new product offerings. Cost optimization initiatives, operational scale, and tech-driven efficiency improvements are enhancing profitability while product portfolio diversification increases market competitiveness and revenue streams.Read more
0users have liked this narrative
0users have commented on this narrative
34users have followed this narrative
AN
US$82.1
18.2% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
12.36% p.a.
Profit Margin
6.78%
Future PE
69.51x
Share price in 2028
US$101.3
AI And Genomics Will Expand Screening For Aging Markets
Key Takeaways Faster-than-expected adoption of new products and AI-driven patient engagement may drive earlier and stronger recurring revenue and margin improvements than anticipated. Expansion into multi-cancer detection and blood-based diagnostics, combined with operational efficiencies, positions the company for leadership in diagnostics and sustained higher profitability.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$77.68
13.6% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
14.42% p.a.
Profit Margin
15.39%
Future PE
28.41x
Share price in 2028
US$95.04
Rising Reimbursement Pressures And Regulatory Hurdles Will Dampen Future Prospects
Key Takeaways Intensifying reimbursement pressure and regulatory scrutiny threaten revenue growth, profitability, and operational efficiency as competition and policy shifts erode pricing power. Heavy investment in R&D, high reliance on key products, and narrowing technological differentiation increase vulnerability to losses, disruption, and abrupt market share declines.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$47.73
40.7% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
9.04% p.a.
Profit Margin
4.53%
Future PE
68.59x
Share price in 2028
US$58.45
Snowflake Analysis
Exact Sciences Corporation Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -5.21
- 69.42%
- -32.01%
- 93.0%
About EXAS
- Founded
- 1995
- Employees
- 6950
- CEO
- WebsiteView website
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
